BROOKSNSEBrooks Laboratories Limited· PharmaceuticalsMediumNeutral
Announced Thu, 14 May · 19:03 IST

Update On Scheme Of Arrangement Involving Brooks Steriscience Limited ('BSL'), A Joint Venture / Associate Of The Company.

Deal CancelledStrategic Transactions View source PDF

BROOKS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-4.1%1-day move
₹48.47
prior close
₹48.83
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.0-0.1-2.7-2.8-4.1-0.1+2.7+5.9+10.9+22.2+38.2+40.3+42.8
Up moveDown movePending
AI summary

Brooks Steriscience Limited (BSL), a Joint Venture/Associate of Brooks Laboratories, has decided not to proceed with the proposed composite scheme of arrangement and amalgamation. The scheme involved Steriscience Specialties, BSL, Steriscience Pte. Limited, Strides Pharma Services, and Onesource Specialty Pharma Limited. BSL's Board deliberated the transaction and concluded it is not in the best interest of stakeholders to pursue it in its current form. This effectively cancels the planned merger activity in the pharma sector.

Likely market impact

BSL has withdrawn from the proposed scheme, meaning Brooks Laboratories will not see any structural change through this particular transaction. No immediate impact on Brooks Laboratories standalone operations, though the strategic rationale for the JV arrangement now remains uncertain.